Astria Therapeutics, Inc.ATXSNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
3.51%
↑ 109% above average
Average (39q)
-37.95%
Historical baseline
Range
High:97.26%
Low:-1792.12%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 3.51% |
| Q2 2025 | 1.72% |
| Q1 2025 | -28.89% |
| Q4 2024 | -4.65% |
| Q3 2024 | 0.00% |
| Q2 2024 | -13.16% |
| Q1 2024 | 55.81% |
| Q4 2023 | -36.51% |
| Q3 2023 | -40.00% |
| Q2 2023 | -12.50% |
| Q1 2023 | 39.39% |
| Q4 2022 | 24.14% |
| Q3 2022 | -1.16% |
| Q2 2022 | 26.50% |
| Q1 2022 | -58.11% |
| Q4 2021 | -21.31% |
| Q3 2021 | 51.20% |
| Q2 2021 | 97.26% |
| Q1 2021 | -1792.12% |
| Q4 2020 | 28.27% |
| Q3 2020 | -5.66% |
| Q2 2020 | -6.00% |
| Q1 2020 | -20.48% |
| Q4 2019 | 25.89% |
| Q3 2019 | 9.68% |
| Q2 2019 | 0.53% |
| Q1 2019 | 0.27% |
| Q4 2018 | 21.87% |
| Q3 2018 | 59.60% |
| Q2 2018 | 31.29% |
| Q1 2018 | -39.21% |
| Q4 2017 | 33.44% |
| Q3 2017 | 2.81% |
| Q2 2017 | 22.42% |
| Q1 2017 | 12.14% |
| Q4 2016 | 13.48% |
| Q3 2016 | 11.67% |
| Q2 2016 | -0.03% |
| Q1 2016 | 2.18% |
| Q4 2015 | -13.19% |